<DOC>
	<DOCNO>NCT02118428</DOCNO>
	<brief_summary>The trial evaluate efficacy Mirasol Pathogen Reduction Technology Whole Blood prevent Malaria transmission transfusion whole blood .</brief_summary>
	<brief_title>Clinical Biological Efficacy Mirasol-treated Fresh Whole Blood Prevention Transfusion-transmitted Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<criteria>Age ≥ 18 year Patient blood group O+ Anticipated hospitalize least 3 consecutive day initial study transfusion Expected require 2 unit Fresh Whole Blood 3 day follow randomization Agree return hospital followup visit Women Child Bearing Potential must negative pregnancy test within 72 hour randomization warrant must agree practice medically acceptable contraception regimen agree abstain heterosexual intercourse study participation . Patient legally authorize representative give write informed consent Symptoms clinical malaria ( confirm microscopy ) Patient receive antimalarial treatment within 7 day prior randomization Fever ( Central body temperature great 38.5°C ) Massive bleeding expect require two Fresh Whole Blood unit within 3 day randomization Transfusion ( ) blood product within 1 month prior randomization Acute chronic medical disorder , opinion investigator , would impair ability patient receive protocol treatment Previous treatment pathogenreduced blood product Females pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>whole blood</keyword>
	<keyword>transfusion</keyword>
	<keyword>Plasmodium</keyword>
	<keyword>Malaria</keyword>
	<keyword>Pathogen Reduction Technology</keyword>
	<keyword>Whole blood transfusion</keyword>
</DOC>